214 related articles for article (PubMed ID: 29854295)
1. ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.
Bado I; Pham E; Soibam B; Nikolos F; Gustafsson JÅ; Thomas C
Oncotarget; 2018 Apr; 9(32):22509-22522. PubMed ID: 29854295
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
4. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Lu W; Katzenellenbogen BS
Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
8. Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.
Datta J; Willingham N; Manouchehri JM; Schnell P; Sheth M; David JJ; Kassem M; Wilson TA; Radomska HS; Coss CC; Bennett CE; Ganju RK; Sardesai SD; Lustberg M; Ramaswamy B; Stover DG; Cherian MA
Front Oncol; 2022; 12():857590. PubMed ID: 35574319
[TBL] [Abstract][Full Text] [Related]
9. ERβ modulates genistein's cisplatin-enhancing activities in breast cancer MDA-MB-231 cells via P53-independent pathway.
Liu R; Xu X; Liang C; Chen X; Yu X; Zhong H; Xu W; Cheng Y; Wang W; Wu Y; Yu L; Hu X
Mol Cell Biochem; 2019 Jun; 456(1-2):205-216. PubMed ID: 30737644
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
Altundag O; Altundag K; Gunduz M
Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor β as a Possible Double-Edged Sword Molecule in Breast Cancer: A Mechanism of Alteration of Its Role by Exposure to Endocrine-Disrupting Chemicals.
Hirao-Suzuki M
Biol Pharm Bull; 2021; 44(11):1594-1597. PubMed ID: 34719637
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
Gougelet A; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
[TBL] [Abstract][Full Text] [Related]
14. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
Liu W; Ip MM; Podgorsak MB; Das GM
Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Use of Estrogen Receptor β Agonists in Prevention and Treatment of Endocrine Therapy Resistant Breast Cancers: Observations From Preclinical Models.
Ramasamy K; Samayoa C; Krishnegowda N; Tekmal RR
Prog Mol Biol Transl Sci; 2017; 151():177-194. PubMed ID: 29096893
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
20. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.
Chang EC; Frasor J; Komm B; Katzenellenbogen BS
Endocrinology; 2006 Oct; 147(10):4831-42. PubMed ID: 16809442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
